Dotatate
- Generic Name
- Dotatate
- Drug Type
- Small Molecule
- Chemical Formula
- C65H90N14O19S2
- CAS Number
- 177943-88-3
- Unique Ingredient Identifier
- MRL3739G66
A Clinical Study to Evaluate the Safety and Efficacy of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms
- Conditions
- Advanced Neuroendocrine Neoplasm
- Interventions
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Sinotau Pharmaceutical Group
- Target Recruit Count
- 74
- Registration Number
- NCT06398444
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors
- Conditions
- Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2023-06-08
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- Peking University
- Target Recruit Count
- 40
- Registration Number
- NCT05894486
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
- Conditions
- Advanced Gastroenteropancreatic Neuroendocrine Tumor
- Interventions
- Drug: long-acting Octreotide.
- First Posted Date
- 2023-06-01
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT05884255
- Locations
- 🇨🇳
Tianjin University Cancer Institute and Hospital, Tianjin, Tianjin, China
Study of Dotatate Imaging in Breast Cancer
- Conditions
- Breast Cancer Stage IV
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Hoag Memorial Hospital Presbyterian
- Target Recruit Count
- 30
- Registration Number
- NCT05880394
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Irvine, California, United States
A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs
- Conditions
- Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Sinotau Pharmaceutical Group
- Target Recruit Count
- 196
- Registration Number
- NCT05459844
- Locations
- 🇨🇳
The First Afilliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
🇨🇳Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC
- First Posted Date
- 2020-03-06
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT04298541
- Locations
- 🇺🇸
Weill Cornell Medical College of Cornell University, New York, New York, United States
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- Conditions
- Neuroendocrine TumorsVon Hippel-Lindau DiseaseVHL Pancreatic Neuroendocrine Tumors
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 740
- Registration Number
- NCT04074135
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
PET Imaging in Patients With Suspected Cardiac Sarcoidosis
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 20
- Registration Number
- NCT03746847
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Somatostatin Receptor Imaging in Cardiac Sarcoidosis
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2020-10-14
- Lead Sponsor
- Rigshospitalet, Denmark
- Registration Number
- NCT02812849
- Locations
- 🇩🇰
Rigshospitalet, Copenhagen, Denmark
Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis
- Conditions
- Sarcoidosis
- Interventions
- Drug: Indium-111 Pentreotide
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- Marcelo F. Di Carli, MD, FACC
- Target Recruit Count
- 17
- Registration Number
- NCT02546388
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.